Navigation Links
Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
Date:5/11/2009

orward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing and completion of clinical trials of Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave or Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and the FDA may not agree with the Company's interpretation of efficacy and safety results; the potential that earlier clinical trials may not be predictive of future results; Contrave may not receive regulatory approval on a timely basis or at all; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual prope
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
2. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
3. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
4. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
11. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... consumers, are increasingly searching for food alternatives that ... nutritional benefits. The food ingredient market has numerous ... players such as Vital Force Technology (VFT). ... more than 4,000 energetic patterns, all tested to ...
(Date:7/31/2014)... 2014 Nearly 20,000 medical professionals and healthcare ... & Clinical Lab Expo in Chicago ... in diagnostic research and technology that will advance medicine ... As of Wednesday, July 30, more than 19,500 attendees ... Clinical Lab Expo, with more than 10,000 of these ...
(Date:7/31/2014)... ability to see through organs and even the entire ... as fine-grained cellular structures has been a long-time dream ... Press July 31st in the journal Cell ... methods for making opaque organs, bodies, and human tissue ... intact. The protocols could pave the way for a ...
(Date:7/31/2014)... SPRINGS, Colo. , July 31, 2014 /PRNewswire-USNewswire/ ... Grant awardee today with $25,000 to fund a ... Foundation,s inception in 2011, the gift was presented ... th Annual Meeting in Colorado ... who specialize in neurointerventional approaches to neurovascular conditions, ...
Breaking Biology Technology:Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... DirectorFAIRFAX, Va., Feb. 25 Edmond Scientific Company ... our team of Tony Mallia as Practice Director. ... bringing to bear his experience of enterprise integration in ... financial services sectors. The core goal of this methodology ...
... plastic surgeryMEDFORD, Mass., Feb. 25 Serica ... developing silk-based biomaterial platforms for tissue regeneration, ... from the U.S. Food and Drug Administration ... long term bioresorbable scaffold technology."We are delighted ...
... 25 Bio-Matrix Scientific Group,Inc. (OTC Bulletin Board: BMSN) ... created positions on its management team. Feng Lin, M.D., ... Laboratory/Scientific,Director and Marilyn Panahi is serving as Quality Assurance ... and Marilyn Panahi bring tremendous expertise to the,administrative operations ...
Cached Biology Technology:Edmond Scientific Company 'Spotlight on the Executive': 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4Bio-Matrix Scientific Group Announces New Hires to Management Team 2
(Date:8/1/2014)... enormous opportunities for both biological and future clinical ... cells in the body, offering immense hope of ... kidney, liver and lung diseases and making damaged ... Prof. Jinhui Chen from Indiana University in USA ... myriad biological, ethical, legal, political, and financial challenges. ...
(Date:8/1/2014)... Colo., USA One of the most diverse families ... as Lucinidae (or lucinids) -- originated more than 400 ... and life habits like those of its modern members. ... the University of Hawaii, published online on 25 July ... through significant symbiotic relationships. , At is origin, the ...
(Date:8/1/2014)... -- LiveScan Service Provider Binary Biometrics is pleased to welcome Kevin ... will improve its mobile service capabilities and add more daily appointments, which will ... service several new cities such as, but not limited to, Daytona ... Deltona , Edgewater , Holly ... Beach , Oak Hill , Orange City ...
Breaking Biology News(10 mins):Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3
... great at protecting leaves from being chomped by slugs, suggests ... . Although they lurk in the soil, they seem to ... the amount of damage slugs do to individual plants. ... 100 worst alien species in Europe and are considered a ...
... more than 13,000 men identified four new genetic variants ... most commonly diagnosed type in young men today. The ... 12 in Nature Genetics by researchers at ... of Pennsylvania . The discovery of these genetic ...
... anomalous pulmonary venous connection (TAPVC), one type of "blue ... occurs when pulmonary veins don,t connect normally to the ... oxygenated blood throughout the body, and TAPVC babies are ... , TAPVC is usually detected in newborns when babies ...
Cached Biology News:Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 2Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 3Mutation causing wrong-way plumbing explains 1 type of blue-baby syndrome 2
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by the lipoxygenation of linoleic acid ... detected in atherosclerotic plaques, as an esterified component ...
Biology Products: